Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
In addition to anti-tumor activity, these compounds have been shown to be potent irreversible inhibitors of P-glycoprotein, a member of the ABC transporter protein family that has a major role in conferring multi-drug resistance. More
Neomics has found a very promising target, AIMP2/AIMP2-DX2 for siRNA therapy application to tumoric lung cancer cells and we intend to focus the remaining resources on developing through clinical trials, the siRNA therapy as a first priority More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
Two isolate Chinese hamster cell lines useful in screening for chemotherapeutic drugs targeting the pathways. More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
A powerful technology for the simultaneous monitoring of protein kinase activities in cell and tissue extracts using a multiplexed electrochemical assay More
Through in vitro and in vivo tumor suppression experiments, the inventors have demonstrated that DLC-1 acts as a new tumor suppressor gene for different types of human cancer. More
New monoclonal antibodies against megakaryocyte potentiation factor More
Adrenomedullin peptides and antibodies, which would be useful in the development of a therapeutic or for diagnostics use More
A novel method for determining the prognosis of a subject with adenocarcinoma in an organ and to aid in the selection of a specific therapeutic regimen. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Adenocarcinoma
- Large Cell carcinoma
- Malignant mesothelioma
- Squamous cell carcinoma
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us